Estrogens, lipoproteins, and cardiovascular risk factors: An update following the randomized placebo-controlled trials of hormone-replacement therapy

Current Opinion in Lipidology

Volumn 15, Issue 4, 2004, Pages 459-467

  Seed, Mary ^a   Knopp, Robert H ^b  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b Division of Metabolism Endocrinology and Nutrition   (United States)

Author keywords

Cardiovascular risk factors; Estrogen; Hormone replacement therapy; Randomised trials

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ARTERY WALL; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; ENDOTHELIUM CELL; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEREDITY; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; RISK ASSESSMENT;

ARTERIES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LIPID METABOLISM; LIPOPROTEINS; MENOPAUSE; PLACEBOS; POSTMENOPAUSE; RISK FACTORS;

EID: 4043174196     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000137231.84772.80     Document Type: Review

References (55)

1. Grodstein F, Stamfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336:1769-1775.
2. Hulley S, Grady D, Bush T, et al. For the HERS Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613.
3. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343:522-529.
4. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study Follow-up (HERS II). JAMA 2002; 288:49-57.
5. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study Follow-up (HERS II). JAMA 2002; 288:58-66.
6. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-534. The final detailed results of the primary prevention WHI, an epidemiological tour de force.
7. The Women's Hearth Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Hearth Initiative Randomized Controlled Trial. JAMA 2004; 291:1701-1712. The full report on the estrogen alone arm of the WHI trial; an important contribution to the subject.
8. Hulley SB, Grady D. The WHI estrogen alone trial - do things look any better? JAMA 2004; 291:1769-1771. A thoughtful editorial on the above study, with a hazard ratio table comparing the three hormone replacement trials.
9. Lawton B, Rose S, McLeod D, Dowell A. Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross-sectional survey of users. BMJ 2003; 327:845-846. A brief and revealing communication from the efficient New Zealand healthcare system.
10. Hersh AI, Stefanick MA, Stafford RS. National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. JAMA 2004; 291:47-53. An exhaustive analysis of changes in prescribing of HRT in the USA (relating chiefly to CEE + MPA use) since trial reports.
11. Kuller LH. Hormone replacement therapy and risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23:11-16. A succinct review of trials, with excellent tables.
12. Burger H. Hormone replacement in the post-Women's Health Initiative era. Climacteric 2003; 6:11-36. An endocrinologist's view, especially relevant on the pharmacological effects of CEE as compared with 17β-estradiol and transdermal therapy. It also highlights differences between the trial population and patients treated with HRT in clinical practice.
13. Biscup P. Risks and benefits of long-term hormone replacement therapy. Am J Health Syst Pharm 2003; 60:1419-1425.
14. Yasui T, Uemura H, Takikawa M, Irahara M. Hormone replacement therapy in postmenopausal women. J Med Invest 2003; 50:136-145.
15. Teede HJ. Hormone replacement therapy, cardiovascular and cerebrovascular disease. Best Pract Res Clin Endocrin Metab 2003; 17:73-90.
16. Knopp RH, Aikawa K, Knopp EA. Estrogen therapies, lipids, and the heart disease prevention controversy. Curr Cardiol Rep 2003; 5:477-482.
17. Herrington DM, Klein KP. Randomized clinical trials of hormone replacement therapy for treatment or prevention of cardiovascular disease: a review of the findings. Atherosclerosis 2003; 166:203-212.
18. Lamon-Fava S, Posfai B, Asztalos BF, et al. Effects of estrogen and medroxyprogesterone acetate on subpopulations of triglyceride-rich lipoproteins and high density lipoproteins. Metabolism 2003; 52:1330-1336. A comprehensive study of changes in lipoprotein subfractions from the prestigious Schaefer laboratory.
19. Ossewaarde ME, Dallinga-Thie GM, Bots ML, et al. Treatment with hormone replacement therapy lowers remnant lipoprotein particles in healthy postmenopausal women: results from a randomized trial. Eur J Clin Invest 2003; 33:376-382. Careful work on the effects of HRTs on flow-mediated dilatation - a surrogate marker of cardiovascular risk - with an excellent discussion.
20. McNamara JR, Shah PK, Nakajima K, et al. Remnant-lipoprotein particle (RLPs) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham heart study. Atherosclerosis 2001; 154:229-236.
21. Leary ET, Wang T, Baker DJ, et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle cholesterol in serum and plasma. Clin Chem 1998; 44:2490-2498.
22. McLintock LA, Dykes A, Tait RC, Walker ID. Interaction between hormone replacement therapy preparations and oral anticoagulant therapy. Br J Obstet Gynaeool 2003; 110:777-779.
23. Wakatsuki A, Okatani Y, Ikenoue N, et al. Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2003; 108:808-813. This important aspect has been unexplored recently. The findings here are highly relevant to dose considerations.
24. Shlipak MG, Chaput LA, Vittinghof E, et al. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). Am Heart J 2003; 146:870-875. Careful analysis of HERS lipid changes, which does not resolve the problem of the failure of these changes to impact on trial outcome.
25. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97:1453-1460.
26. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2002; 283:1845-1852.
27. Berg K, Dahlén G, Christophersen B, et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997; 52:254-261.
28. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151:1141-1147.
29. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138:1-9. A particularly enlightened approach to an epidemiological problem, with the result being neatly extracted from the available data.
30. Wilson PWF. Lower diabetes risk with hormone replacement therapy: an encore for estrogen? Ann Intern Med 2003; 138:69-70.
31. Ferrara A, Quesenberry CP, Karter AJ, et al. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes. Circulation 2003; 107:43-48. This large 3-year study, although inevitably not correcting entirely for bias, has been meticulously carried out.
32. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham study. N Engl J Med 1985; 313:1038-1043.
33. 1c levels. Diabetes Care 2003; 26:1088-1092.
34. Stojanovic ND, Kwong P, Byrne DJ, et al. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. Angiology 2003; 54:391-399.
35. Ching HL, Watts GF, Dhaliwal SS, et al. Vascular function of forearm microcirculation in postmenopausal women with type 2 diabetes: potential benefit of hormone replacement therapy? Climacteric 2003; 6:31-37. A painstaking study of endothelial function as a measure of cardiovascular health, with a good discussion.
36. Koh KK. Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy? Int J Cardiol 2003; 87:1-8. A thoughtful review, by an experienced worker in the field, of the different effects of estrogen on intact and damaged endothelium.
37. Chiantera V, Sarti CD, Fornaro F, et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 2003; 4:286-291.
38. Giltay EJ, Verhoef P, Gooren LJG, et al. Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals. Atherosclerosis 2003; 168:139-146.
39. Koh KK, Ahn JY, Jin DK, et al. Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women. Arterioscler Thromb Vasc Biol 2002; 22:1459-1464.
40. Koh KK, Ahn JY, Jin DK, et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23:1889-1894.
41. Störk S, von Schacky C, Angerer P. The effect of 17β-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis 2002; 165:301-307.
42. Silvestri A, Gebara O, Vitale C, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003; 107:3165-3169. An intriguing and plausible thesis, well argued but difficult to prove.
43. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23:1671-1676. An excellent double-blind placebo controlled parallel group trial, adequately powered to determine differences in the hemostatic parameters measured.
44. Spengler MI, Goñi GM, Mengarelli G, et al. Effect of hormone replacement therapy upon hemorheological variables. Clin Hemorheol Microcirc 2003; 28:13-19.
45. Os I, Høieggen A, Larsen A, et al. Smoking and relation to other risk factors in postmenopausal women with coronary artery disease, with particular reference to whole blood viscosity and β-cell function. J Intern Med 2003; 253:232-239.
46. Scarabin P-Y, Oger E, Plu-Bureau G, on behalf of the Estrogen and Thromboembolism Risk (ESTHER) Study Group. Differential association of oral and transdermal estrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362:428-432. As to be expected from the INSERM Cardiovascular Epidemiology Unit, a solid and convincing study on differing metabolic/hemostatic effects of HRT according to route of administration.
47. Le Gal G, Gourlet V, Hogrel P, et al. Hormone replacement therapy use is associated with a lower occurrence of carotid artery plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. Atherosclerosis 2003; 166:163-170. A useful vascular outcome study of the effect of transdermal HRT.
48. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135:939-953.
49. Wakatsuki A, Ikenoue N, Shinohara K, et al. Different effects of oral and transdermal estrogen replacement therapy on matrix metalloproteinase and their inhibitor in postmenopausal women [letter]. Arterioscler Thromb Vasc Biol 2003; 23:1948 . Good experimental work, with the important finding of a differential effect of oral and transdermal therapy on matrix metalloproteinase which may be crucial in secondary prevention.
50. Mikkola TS, Anthony MS, Clarkson TB, St Clair RW. Serum cholesterol efflux potential is an independent predictor of coronary artery atherosclerosis. Atherosclerosis 2003; 170:31-38.
51. Clarkson TB, Anthony MS, Klein KP. Hormone replacement therapy and coronary artery atherosclerosis: the monkey model. Br J Obstet Gynecol 1996; 103(suppl 13):53-57.
52. Gourdy P, Mallat Z, Castano C, et al. The atheroprotective effect of 17β-estradiol is not altered in P-selectin- or ICAM-1-deficient hypercholesterolemic mice. Atherosclerosis 2003; 166:41-48. An intriguing study on mechanism, using the ApoE-deficient mouse model.
53. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary artery disease. N Engl J Med 2002; 346:967-974.
54. Herrington DM, Howard TD, Brosnihan B, et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002; 105:1879-1882.
55. Ferrero V, Ribichini F, Matullo G, et al. Estrogen receptor-a polymorphisms and angiographic outcome after coronary artery stenting. Arterioscler Thromb Vasc Biol 2003; 23:2223-2228. An interesting approach to factors affecting in-stent restenosis in women, which although not clinically useful at present is likely to form the basis for selection of appropriate stents in the future.